Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Brodalumab/Ixekizumab/Secukinumab

Crohn's disease

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wilson J, et al. Inflammatory Bowel Disease Unmasked by Interleukin-17 Inhibitor for Psoriasis. American Journal of Gastroenterology 118 (Suppl.): S15, No. 12, Dec 2023 [abstract] Wilson J, et al. Inflammatory Bowel Disease Unmasked by Interleukin-17 Inhibitor for Psoriasis. American Journal of Gastroenterology 118 (Suppl.): S15, No. 12, Dec 2023 [abstract]
Metadaten
Titel
Brodalumab/Ixekizumab/Secukinumab
Crohn's disease
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57279-7

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Clozapine

Case report

Rivoceranib

Case report

Dupilumab

Case report

Phenytoin

Case report

Hydroxycarbamide